



Syndax Pharmaceuticals, Inc.
Investor Relations Department
35 Gatehouse Drive
Building D, Floor 3
Waltham, MA 02451
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: SNDX

Last Trade:	12.05
Trade Time:	4:00 PM ET 10.18.17
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	6.31 - 15.70
Volume	N/A


Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 10.17.17 [Syndax Announces \\$25 Million Registered Direct Offering of Common Stock](#)
- 10.17.17 [Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors](#)
- 10.05.17 [Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin](#)
- 09.20.17 [Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference](#)
- 08.30.17 [Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences](#)

Financial Information [\[View all \]](#)

- [Second Quarter Financial Results](#)
- 03.14.17 [Annual Report \(10-K\)](#)
- 04.07.17 [Proxy Statement \(DEF 14A\)](#)
- 08.10.17 [Quarterly Report \(10-Q\)](#)
- 05.09.17 [Quarterly Report \(10-Q\)](#)
- 11.14.16 [Quarterly Report \(10-Q\)](#)